An estrogen antagonist of potential value in the treatment of advanced human renal adenocarcinoma, and perhaps other types of cancer in which estrogen dependency may be a factor, has been investigated experimentally. The drug, U.11,100A, a diphenyldihydronaphthalene derivative, markedly inhibited the growth of a transplanted estrogen-induced renal tumor in hamsters. The life of treated animals was substantially prolonged compared with that of control groups; after 5 weeks all animals receiving U.11,100A were alive and well with small tumors whereas all the controls injected with the solvent only had been killed because of large tumors with commencing ulceration. Seven of the 11 treated animals survived for 13 to 15 weeks before they had to be killed because of large tumors. The tumor inhibitory effect of U.11,100A was abolished largely by the simultaneous administration of estradiol, which suggests that this activity of the drug is related to its antiestrogenic properties.
No takes yet. Share an insight, caveat, or question.
Bloom et al. (1967) studied this question.